In this webinar, Dr. Joseph Zabinski will discuss the digital phenotyping process and several concrete applications to demonstrate how AI can add value to analyses of the patient journey across the life sciences spectrum.

Real-world data provide insight into patient journeys, including around diagnosis, progression, and treatment. These insights are limited by what’s available in the data, and traditional techniques can leave key questions unanswered: the true size of a population of interest including those diagnosed and undiagnosed, for example, or whether particular patients are at higher risk of disease progression and need earlier treatment. Using applied AI, we can gain insight into these open questions. AI-powered Digital phenotyping uses real-world data to isolate ‘fingerprints’ – patterns of information shared by patients with a characteristic of interest – that we can use to better identify and understand key patient subgroups.

Key Topics Include:

  • Demystify AI and demonstrate its application alongside other methods of real-world data analysis
  • Understand how AI can be applied to real-world data to create digital ‘phenotypes’ for target patient groups
  • Review examples of digital phenotyping adding insight to patient journey analyses inaccessible through other means
  • Evaluate the utility of digital phenotyping for answering questions around diagnosis, progression, and treatment

Presenters

Joseph Zabinski, ;PhD, MEM

Joseph Zabinski, PhD, MEM

VP, Head of Commercial Strategy & AI
OM1

Dr. Joseph Zabinski oversees design, implementation, and evolution of OM1's commercial strategy, including prioritization, GTM planning, and alignment with emergent market needs. Dr. Zabinski also serves as SME and thought leader for OM1's AI work, including applications of the PhenOM digital phenotyping platform with life science and healthcare provider partners.

Production Partner

Additional Content From OM1

Related Content

Synthesise RWE and AI. Transform patient-driven healthcare

Synthesise RWE and AI. Transform patient-driven healthcare

As the volume of the real word evidence data increases, the mechanisms to collect and translate the data into meaningful insights for pharmaceutical organisations becomes increasingly complex. Advances in technologies such as artificial technology have delivered global excitement, but mastering how to leverage AI for meaningful patient outcomes remains uncracked.
Transforming clinical research: Scaling real-world data across diseases with expert-led AI

Transforming clinical research: Scaling real-world data across diseases with expert-led AI

The promise of improving patient care and outcomes through RWD has been understood for some time, but overcoming the fragmentation and inaccessibility of disparate data sources across disease states has proven to be a hard challenge across the industry. We’re not learning fast enough— this is where clinical expert-led AI can help. By using AI to standardize unprecedented volumes of data, uncover clinical details that have previously been hidden in free text notes, and represent full patient journeys in near real-time, researchers can ask and answer complex questions for targeted populations like never before.